Table 3.

Cox proportional hazard model for depth of response

	Unadjusted OS HR (95% CI)	Adjusted OS HR (95% CI)*	Unadjusted PFS HR (95% CI)	Adjusted PFS HR (95% CI)*
ALK inhibitor DepOR subgroups (n = 305)
No tumor shrinkage (n =12)
1%–25% (n =39)	0.98 (0.36, 2.69)	0.94 (0.34, 2.61)	0.19 (0.09, 0.39)	0.19 (0.09, 0.40)
26%–50% (n =70)	0.66 (0.25, 1.75)	0.56 (0.21, 1.51)	0.12 (0.06, 0.24)	0.11 (0.06, 0.24)
51%–75% (n =144)	0.38 (0.15, 0.96)	0.28 (0.11, 0.73)	0.06 (0.03, 0.12)	0.05 (0.03, 0.11)
76%–100% (n =40)	0.06 (0.01, 0.33)	0.05 (0.01, 0.28)	0.03 (0.02, 0.07)	0.03 (0.02, 0.07)
PD-1 inhibitor DepOR subgroups (n =355)
No tumor shrinkage (n =168)
1%–25% (n =70)	0.54 (0.38, 0.76)	0.52 (0.37, 0.74)	0.30 (0.22, 0.41)	0.30 (0.22, 0.41)
26%–50% (n =44)	0.50 (0.32, 0.78)	0.47 (0.30, 0.74)	0.22 (0.15, 0.32)	0.22 (0.15, 0.32)
51%–75% (n =45)	0.09 (0.04, 0.21)	0.07 (0.03, 0.18)	0.10 (0.06, 0.15)	0.09 (0.06, 0.15)
76%–100% (n =28)	0.14 (0.06, 0.31)	0.14 (0.06, 0.32)	0.06 (0.03, 0.12)	0.07 (0.03, 0.12)

*Adjusted by study, ECOG, and smoking status